Best available therapy (BAT): Clinical Trials

13 trials of Best available therapy (BAT), newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

6 completed, 3 active not recruiting, 2 not yet recruiting, 1 recruiting. 12 Phase 3, 2 Phase 2.

By phase and status

Phase	Trials	Status
Phase 3	12	Completed 6, Active not recruiting 3, Not yet recruiting 1, Recruiting 1, Unknown 1
Phase 2	2	Not yet recruiting 1, Unknown 1

Follow Best available therapy (BAT): new trials by email Literature Review of Best available therapy (BAT) trials Research Report on Best available therapy (BAT)

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease Belumosudil, Best available therapy (BAT) - Chronic Graft Versus Host Disease	Phase 3	Not yet recruiting	Sanofi	356	2026-09-07	2026-09-15
Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex BV100 with 50 mg polymyxin B plus ceftazidime/avibactam, BV100 with 50 mg polymyxin B plus cefiderocol, Best Available Therapy (BAT) - Ventilator Associated Bacterial Pneumonia (VABP), Hospital Acquired Bacterial Pneumonia (HABP)	Phase 2	Not yet recruiting	BioVersys AG	120	2026-07-01	2026-02-24
A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy INCA034176, Best Available Therapy (BAT) - Chronic Graft-versus-host-disease	Phase 3	Active not recruiting	Incyte Corporation	9	2025-06-04	2026-08-25
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment Imetelstat, Best Available Therapy (BAT) - Myelofibrosis	Phase 3	Active not recruiting	Geron Corporation	327	2021-04-12	2026-07-08
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis Navitoclax, Ruxolitinib, Best Available Therapy (BAT) - Myelofibrosis (MF)	Phase 3	Active not recruiting	AbbVie	330	2020-08-31	2026-01-09
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) Autologous Hematopoietic Stem Cell Transplantation, Best Available Therapy (BAT) - Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis	Phase 3	Recruiting	National Institute of Allergy and Infectious Diseases (NIAID)	156	2020-08-17	2026-10-20
An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib FEDRATINIB, Best Available Therapy (BAT) - Primary Myelofibrosis, Post-Polycythemia Vera	Phase 3	Completed	Celgene	202	2019-09-09	2025-08-28
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment KRT-232, Best Available Therapy (BAT) - Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF)	Phase 2 / Phase 3	Unknown	Kartos Therapeutics, Inc.	385	2019-01-15	2023-04-28
Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation Ruxolitinib (RUX), Best Available Therapy (BAT) - Corticosteroid Refractory Acute Graft vs Host Disease	Phase 3	Completed	Novartis Pharmaceuticals	310	2017-03-10	2023-02-08
AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study. Pegylated-Proline-interferon alpha-2b, Best available therapy (BAT) - Polycythemia Vera	Phase 3	Completed	AOP Orphan Pharmaceuticals AG	170	2014-11-01	2021-06-01
Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF Momelotinib, Best Available Therapy (BAT) - Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV)	Phase 3	Completed	Sierra Oncology LLC - a GSK company	156	2014-06-19	2023-05-23
Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial) ruxolitinib tablets, Best Available Therapy (BAT) - Polycythemia Vera	Phase 3	Completed	Incyte Corporation	222	2010-10-27	2019-03-06
Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial Ruxolitinib, Best Available Therapy (BAT) - Myelofibrosis	Phase 3	Completed	Novartis Pharmaceuticals	219	2009-07-01	2019-08-19

Conditions studied

Sponsors

Countries

Top investigators

Results publications

NIH funding